Atlanta, GA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its agreement with a five hospital, Epic-EHR based health system in Pennsylvania. The system will add eValuator’s Pro-Fee pre-bill coding analysis technology to improve revenue integrity and financial performance for their professional fee services.
eValuator’s pre-bill code audit technology makes it easy for providers to identify, quantify and expedite correction of coding issues with the highest impact on revenue integrity. With eValuator, providers can optimize financial performance from their inpatient, outpatient, and professional-fee encounters through one platform, without billing delays.
“We are pleased to expand our relationship with this health system and to enable them to audit all of their records, prior to billing, across their continuum of care,” stated Ben Stilwill, Chief Executive Officer. “This expansion is a testament to the value of eValuator and to the strong relationships our Client Success team is building.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
To Learn More
Jacob Goldberger
Director, Investor Relations and FP&A
303.887.9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.98 |
| Daily Change: | -0.42 -12.35 |
| Daily Volume: | 32,177 |
| Market Cap: | US$188.690M |
October 08, 2024 July 16, 2024 July 02, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
